Novo Nordisk will continue to restrict US supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, as the company struggles to keep up with soaring demand.
Read the story here: https://reut.rs/3KB3cPX
Keep up with the latest news from around the world: https://www.reuters.com/
#News #Reuters #newsfeed #weightloss #health #pharma #novonordisk
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Read the story here: https://reut.rs/3KB3cPX
Keep up with the latest news from around the world: https://www.reuters.com/
#News #Reuters #newsfeed #weightloss #health #pharma #novonordisk
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Sign in or sign up to post comments.
Be the first to comment